{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T12:01:19Z","timestamp":1779883279388,"version":"3.53.1"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Schleswig-Holstein - Campus L\u00fcbeck"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) are muco-obstructive lung diseases. Knowledge of molecular processes has much improved therapeutic options in CF, whereas much less is known for COPD, a disease affecting an increasing number of patients. Here, we report a multilayer workflow integrating microbiome, inflammation and proteome profiling with clinical data to identify disease specific characteristics in sputum. Our proof-of-concept study shows that CF sputum is dominated by\n                    <jats:italic>Pseudomonas<\/jats:italic>\n                    and\n                    <jats:italic>Staphylococcus<\/jats:italic>\n                    , exhibits heightened neutrophilic inflammation, and a severe protease-antiprotease imbalance. In contrast, COPD displays heterogeneous microbiome composition, eosinophilic inflammation, and altered extracellular matrix remodeling. Proteome-based cellular deconvolution identifies disease-specific immune cell signatures, underscoring the complexity, especially in COPD. Multi-omics factor analysis suggests that matrisome and nucleotide metabolism changes may act as disease discriminators, though future confirmation in larger cohorts is needed. These findings highlight the potential of our integrated approach to uncover sputum biomarkers as tools for patient stratification and personalized therapeutic strategies in CF and COPD.\n                  <\/jats:p>","DOI":"10.1038\/s41598-025-32565-y","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:23:59Z","timestamp":1766535839000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["SputOMICs identifies common and distinct markers in cystic fibrosis and chronic obstructive pulmonary disease"],"prefix":"10.1038","volume":"15","author":[{"given":"Dario L.","family":"Frey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Helm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Guerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Hagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Susanne","family":"Dittrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Wege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Eberhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix J. F.","family":"Herth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Sommerburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander H.","family":"Dalpke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Klingm\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus A.","family":"Mall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Boutin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"key":"32565_CR1","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1056\/NEJMra1813799","volume":"380","author":"RC Boucher","year":"2019","unstructured":"Boucher, R. C. Muco-Obstructive Lung Diseases. N Engl J Med 380, 1941\u20131953 (2019).","journal-title":"N Engl J Med"},{"key":"32565_CR2","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41572-024-00538-6","volume":"10","author":"MA Mall","year":"2024","unstructured":"Mall, M. A. et al. Cystic fibrosis. Nat Rev Dis Primers 10, 53 (2024).","journal-title":"Cystic fibrosis. Nat Rev Dis Primers"},{"key":"32565_CR3","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/S0140-6736(22)01273-9","volume":"400","author":"D Stolz","year":"2022","unstructured":"Stolz, D. et al. Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission. Lancet 400, 921\u2013972 (2022).","journal-title":"Lancet"},{"key":"32565_CR4","unstructured":"Welsh MJ, Ramsey BW, Accurso F, Cutting GR. Cystic Fibrosis. In: The Online Metabolic and Molecular Bases of Inherited Disease. (eds Valle DL, Antonarakis S, Ballabio A, Beaudet AL, Mitchell GA). (McGraw-Hill Education, 2019)."},{"key":"32565_CR5","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1164\/rccm.200304-505SO","volume":"168","author":"RL Gibson","year":"2003","unstructured":"Gibson, R. L., Burns, J. L. & Ramsey, B. W. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am. J. Respir. Crit. Care Med. 168, 918\u2013951 (2003).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"32565_CR6","doi-asserted-by":"publisher","first-page":"2300239","DOI":"10.1183\/13993003.00239-2023","volume":"61","author":"A Agusti","year":"2023","unstructured":"Agusti, A. et al. Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. Eur. Respir. J. 61, 2300239 (2023).","journal-title":"Eur. Respir. J."},{"key":"32565_CR7","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/S0140-6736(23)01609-4","volume":"402","author":"JL Taylor-Cousar","year":"2023","unstructured":"Taylor-Cousar, J. L., Robinson, P. D., Shteinberg, M. & Downey, D. G. CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis. Lancet 402, 1171\u20131184 (2023).","journal-title":"Lancet"},{"key":"32565_CR8","doi-asserted-by":"publisher","first-page":"2202029","DOI":"10.1183\/13993003.02029-2022","volume":"62","author":"CL Daines","year":"2023","unstructured":"Daines, C. L. et al. Long-term safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from a 192-week open-label extension study. Eur. Respir. J. 62, 2202029 (2023).","journal-title":"Eur. Respir. J."},{"key":"32565_CR9","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1002\/ppul.23190","volume":"50","author":"O Sommerburg","year":"2015","unstructured":"Sommerburg, O. et al. Five years of experience with biochemical cystic fibrosis newborn screening based on IRT\/PAP in Germany. Pediatr. Pulmonol. 50, 655\u2013664 (2015).","journal-title":"Pediatr. Pulmonol."},{"key":"32565_CR10","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/S0140-6736(23)01608-2","volume":"402","author":"SY Graeber","year":"2023","unstructured":"Graeber, S. Y. & Mall, M. A. The future of cystic fibrosis treatment: from disease mechanisms to novel therapeutic approaches. Lancet 402, 1185\u20131198 (2023).","journal-title":"Lancet"},{"key":"32565_CR11","doi-asserted-by":"publisher","first-page":"2202153","DOI":"10.1183\/13993003.02153-2022","volume":"62","author":"L Schaupp","year":"2023","unstructured":"Schaupp, L. et al. Longitudinal effects of elexacaftor\/tezacaftor\/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis. Eur. Respir. J. 62, 2202153 (2023).","journal-title":"Eur. Respir. J."},{"key":"32565_CR12","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1513\/AnnalsATS.202008-1054OC","volume":"18","author":"SY Graeber","year":"2021","unstructured":"Graeber, S. Y. et al. Effects of Lumacaftor-Ivacaftor on Lung Clearance Index, Magnetic Resonance Imaging, and Airway Microbiome in Phe508del Homozygous Patients with Cystic Fibrosis. Ann Am Thorac Soc 18, 971\u2013980 (2021).","journal-title":"Ann Am Thorac Soc"},{"key":"32565_CR13","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(07)61377-4","volume":"370","author":"AS Buist","year":"2007","unstructured":"Buist, A. S. et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 370, 741\u2013750 (2007).","journal-title":"Lancet"},{"key":"32565_CR14","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1378\/chest.15-1752","volume":"149","author":"M Karloh","year":"2016","unstructured":"Karloh, M. et al. The COPD assessment test: what do we know so far?: A systematic review and meta-analysis about clinical outcomes prediction and classification of patients into gold stages. Chest 149, 413\u2013425 (2016).","journal-title":"Chest"},{"key":"32565_CR15","doi-asserted-by":"publisher","first-page":"1900651","DOI":"10.1183\/13993003.00651-2019","volume":"54","author":"C Brightling","year":"2019","unstructured":"Brightling, C. & Greening, N. Airway inflammation in COPD: progress to precision medicine. Eur. Respir. J. 54, 1900651 (2019).","journal-title":"Eur. Respir. J."},{"key":"32565_CR16","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1080\/14789450.2017.1304215","volume":"14","author":"K Fujii","year":"2017","unstructured":"Fujii, K., Nakamura, H. & Nishimura, T. Recent mass spectrometry-based proteomics for biomarker discovery in lung cancer, COPD, and asthma. Expert Rev Proteomics 14, 373\u2013386 (2017).","journal-title":"Expert Rev Proteomics"},{"key":"32565_CR17","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.2147\/COPD.S308305","volume":"16","author":"SH Kim","year":"2021","unstructured":"Kim, S. H. et al. A proteomics-based analysis of blood biomarkers for the diagnosis of COPD acute exacerbation. Int. J. Chron. Obstruct. Pulmon. Dis. 16, 1497\u20131508 (2021).","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"32565_CR18","doi-asserted-by":"publisher","first-page":"L17","DOI":"10.1152\/ajplung.00082.2015","volume":"309","author":"J Gao","year":"2015","unstructured":"Gao, J. et al. Elevated sputum BPIFB1 levels in smokers with chronic obstructive pulmonary disease: a longitudinal study. Am. J. Physiol. Lung Cell Mol. Physiol. 309, L17-26 (2015).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"32565_CR19","doi-asserted-by":"publisher","first-page":"L1155","DOI":"10.1152\/ajplung.00021.2016","volume":"310","author":"S Ohlmeier","year":"2016","unstructured":"Ohlmeier, S. et al. Lung tissue proteomics identifies elevated transglutaminase 2 levels in stable chronic obstructive pulmonary disease. Am. J. Physiol. Lung Cell Mol. Physiol. 310, L1155-1165 (2016).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"32565_CR20","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S2213-2600(17)30432-0","volume":"5","author":"AT Hastie","year":"2017","unstructured":"Hastie, A. T. et al. Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort. Lancet Respir Med 5, 956\u2013967 (2017).","journal-title":"Lancet Respir Med"},{"key":"32565_CR21","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/j.chest.2021.10.049","volume":"161","author":"CR Esther Jr","year":"2022","unstructured":"Esther, C. R. Jr. et al. Identification of sputum biomarkers predictive of pulmonary exacerbations in COPD. Chest 161, 1239\u20131249 (2022).","journal-title":"Chest"},{"key":"32565_CR22","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1136\/thoraxjnl-2017-210408","volume":"73","author":"D Mayhew","year":"2018","unstructured":"Mayhew, D. et al. Longitudinal profiling of the lung microbiome in the AERIS study demonstrates repeatability of bacterial and eosinophilic COPD exacerbations. Thorax 73, 422\u2013430 (2018).","journal-title":"Thorax"},{"key":"32565_CR23","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1016\/S2213-2600(21)00079-5","volume":"9","author":"G Radicioni","year":"2021","unstructured":"Radicioni, G. et al. Airway mucin MUC5AC and MUC5B concentrations and the initiation and progression of chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. Lancet. Respir. Med. 9, 1241\u20131254 (2021).","journal-title":"Lancet. Respir. Med."},{"key":"32565_CR24","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.jcf.2023.10.019","volume":"23","author":"RE Maher","year":"2024","unstructured":"Maher, R. E. et al. Influence of highly effective modulator therapy on the sputum proteome in cystic fibrosis. J. Cyst. Fibros. 23, 269\u2013277 (2024).","journal-title":"J. Cyst. Fibros."},{"key":"32565_CR25","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","volume":"388","author":"JS Elborn","year":"2016","unstructured":"Elborn, J. S. Cystic fibrosis. The Lancet 388, 2519\u20132531 (2016).","journal-title":"The Lancet"},{"key":"32565_CR26","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1164\/rccm.201008-1285OC","volume":"183","author":"E Sapey","year":"2011","unstructured":"Sapey, E. et al. Behavioral and structural differences in migrating peripheral neutrophils from patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 183, 1176\u20131186 (2011).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"32565_CR27","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1038\/s41564-022-01196-8","volume":"7","author":"Z Yan","year":"2022","unstructured":"Yan, Z. et al. Multi-omics analyses of airway host-microbe interactions in chronic obstructive pulmonary disease identify potential therapeutic interventions. Nat. Microbiol. 7, 1361\u20131375 (2022).","journal-title":"Nat. Microbiol."},{"key":"32565_CR28","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.chom.2023.04.018","volume":"31","author":"W Liang","year":"2023","unstructured":"Liang, W. et al. Airway dysbiosis accelerates lung function decline in chronic obstructive pulmonary disease. Cell Host Microbe 31, 1054\u20131070 (2023).","journal-title":"Cell Host Microbe"},{"key":"32565_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0116029","volume":"10","author":"S Boutin","year":"2015","unstructured":"Boutin, S. et al. Comparison of microbiomes from different niches of upper and lower airways in children and adolescents with cystic fibrosis. PLoS ONE 10, e0116029 (2015).","journal-title":"PLoS ONE"},{"key":"32565_CR30","first-page":"e62193","volume":"171","author":"DL Frey","year":"2021","unstructured":"Frey, D. L., Guerra, M., Mall, M. A. & Schultz, C. Monitoring neutrophil elastase and cathepsin G activity in human sputum samples. J. Vis. Exp. 171, e62193 (2021).","journal-title":"J. Vis. Exp."},{"key":"32565_CR31","doi-asserted-by":"publisher","first-page":"885822","DOI":"10.3389\/fmicb.2022.885822","volume":"13","author":"DL Frey","year":"2022","unstructured":"Frey, D. L. et al. Changes in Microbiome Dominance Are Associated With Declining Lung Function and Fluctuating Inflammation in People With Cystic Fibrosis. Front. Microbiol. 13, 885822 (2022).","journal-title":"Front. Microbiol."},{"key":"32565_CR32","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.jcf.2020.12.022","volume":"20","author":"DL Frey","year":"2021","unstructured":"Frey, D. L. et al. Relationship between airway dysbiosis, inflammation and lung function in adults with cystic fibrosis. J. Cyst. Fibros. 20, 754 (2021).","journal-title":"J. Cyst. Fibros."},{"key":"32565_CR33","doi-asserted-by":"publisher","first-page":"1701910","DOI":"10.1183\/13993003.01910-2017","volume":"51","author":"AS Dittrich","year":"2018","unstructured":"Dittrich, A. S. et al. Elastase activity on sputum neutrophils correlates with severity of lung disease in cystic fibrosis. Eur. Respir. J. 51, 1701910 (2018).","journal-title":"Eur. Respir. J."},{"key":"32565_CR34","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/S2213-2600(13)70120-6","volume":"1","author":"JG Peter","year":"2013","unstructured":"Peter, J. G. et al. Comparison of two methods for acquisition of sputum samples for diagnosis of suspected tuberculosis in smear-negative or sputum-scarce people: a randomised controlled trial. Lancet Respir Med 1, 471\u2013478 (2013).","journal-title":"Lancet Respir Med"},{"key":"32565_CR35","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S2213-2600(18)30171-1","volume":"6","author":"K Ronchetti","year":"2018","unstructured":"Ronchetti, K. et al. The CF-Sputum Induction Trial (CF-SpIT) to assess lower airway bacterial sampling in young children with cystic fibrosis: a prospective internally controlled interventional trial. Lancet. Respir. Med. 6, 461\u2013471 (2018).","journal-title":"Lancet. Respir. Med."},{"key":"32565_CR36","doi-asserted-by":"publisher","first-page":"1902355","DOI":"10.1183\/13993003.02355-2019","volume":"55","author":"M Hagner","year":"2020","unstructured":"Hagner, M. et al. New method for rapid and dynamic quantification of elastase activity on sputum neutrophils from patients with cystic fibrosis using flow cytometry. Eur. Respir. J. 55, 1902355 (2020).","journal-title":"Eur. Respir. J."},{"key":"32565_CR37","doi-asserted-by":"publisher","DOI":"10.1093\/bioadv\/vbac004","author":"S Heming","year":"2022","unstructured":"Heming, S. et al. MSPypeline: A python package for streamlined data analysis of mass spectrometry-based proteomics. Bioinformat. Adv. https:\/\/doi.org\/10.1093\/bioadv\/vbac004 (2022).","journal-title":"Bioinformat. Adv."},{"key":"32565_CR38","doi-asserted-by":"publisher","DOI":"10.15252\/msb.20178124","volume":"14","author":"R Argelaguet","year":"2018","unstructured":"Argelaguet, R. et al. Multi-omics factor analysis\u2014a framework for unsupervised integration of multi-omics data sets. Mol. Syst. Biol. 14, e8124 (2018).","journal-title":"Mol. Syst. Biol."},{"key":"32565_CR39","doi-asserted-by":"publisher","first-page":"210241","DOI":"10.1183\/16000617.0241-2021","volume":"31","author":"HR Keir","year":"2022","unstructured":"Keir, H. R. & Chalmers, J. D. Neutrophil extracellular traps in chronic lung disease: implications for pathogenesis and therapy. Eur. Respir. Rev. 31, 210241 (2022).","journal-title":"Eur. Respir. Rev."},{"key":"32565_CR40","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1093\/jleuko\/qiae153","volume":"161","author":"A Higham","year":"2024","unstructured":"Higham, A., Beech, A. & Singh, D. The relevance of eosinophils in chronic obstructive pulmonary disease: inflammation, microbiome and clinical outcomes. J. Leukoc. Biol. 161, 927 (2024).","journal-title":"J. Leukoc. Biol."},{"key":"32565_CR41","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S2213-2600(17)30217-5","volume":"5","author":"M Bafadhel","year":"2017","unstructured":"Bafadhel, M., Pavord, I. D. & Russell, R. E. Eosinophils in COPD: just another biomarker?. Lancet. Respir. Med. 5, 747\u2013759 (2017).","journal-title":"Lancet. Respir. Med."},{"key":"32565_CR42","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.bbrc.2022.07.025","volume":"622","author":"M Volpato","year":"2022","unstructured":"Volpato, M. et al. Rheology predicts sputum eosinophilia in patients with muco-obstructive lung diseases. Biochem. Biophys. Res. Commun. 622, 64\u201371 (2022).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"32565_CR43","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ccm.2013.10.004","volume":"35","author":"PJ Barnes","year":"2014","unstructured":"Barnes, P. J. Cellular and molecular mechanisms of chronic obstructive pulmonary disease. Clin. Chest Med. 35, 71\u201386 (2014).","journal-title":"Clin. Chest Med."},{"key":"32565_CR44","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1164\/ajrccm.150.1.7912987","volume":"150","author":"P Birrer","year":"1994","unstructured":"Birrer, P. et al. Protease-antiprotease imbalance in the lungs of children with cystic fibrosis. Am. J. Respir. Crit. Care Med. 150, 207\u2013213 (1994).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"32565_CR45","doi-asserted-by":"publisher","first-page":"6258","DOI":"10.1002\/anie.201109226","volume":"51","author":"S Gehrig","year":"2012","unstructured":"Gehrig, S., Mall, M. A. & Schultz, C. Spatially resolved monitoring of neutrophil elastase activity with ratiometric fluorescent reporters. Angew. Chem. Int. Ed. 51, 6258\u20136261 (2012).","journal-title":"Angew. Chem. Int. Ed."},{"key":"32565_CR46","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1165\/rcmb.2004-0374OC","volume":"32","author":"B Korkmaz","year":"2005","unstructured":"Korkmaz, B. et al. Competition between elastase and related proteases from human neutrophil for binding to alpha1-protease inhibitor. Am. J. Respir. Cell Mol. Biol. 32, 553\u2013559 (2005).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"32565_CR47","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1002\/pro.64","volume":"18","author":"ML Zani","year":"2009","unstructured":"Zani, M. L., Baranger, K., Guyot, N., Dallet-Choisy, S. & Moreau, T. Protease inhibitors derived from elafin and SLPI and engineered to have enhanced specificity towards neutrophil serine proteases. Protein Sci. 18, 579\u2013594 (2009).","journal-title":"Protein Sci."},{"key":"32565_CR48","doi-asserted-by":"publisher","first-page":"240001","DOI":"10.1183\/16000617.0001-2024","volume":"33","author":"MA Mall","year":"2024","unstructured":"Mall, M. A. et al. Neutrophil serine proteases in cystic fibrosis: role in disease pathogenesis and rationale as a therapeutic target. Eur. Respir. Rev. 33, 240001 (2024).","journal-title":"Eur. Respir. Rev."},{"key":"32565_CR49","first-page":"454","volume":"9","author":"GJ Criner","year":"2022","unstructured":"Criner, G. J. et al. Chronic obstructive pulmonary disease and lung cancer: A review for clinicians. Chronic Obstr. Pulm Dis. 9, 454\u2013476 (2022).","journal-title":"Chronic Obstr. Pulm Dis."},{"key":"32565_CR50","doi-asserted-by":"publisher","first-page":"101371","DOI":"10.1016\/j.xcrm.2023.101371","volume":"5","author":"E Cauwenberghs","year":"2024","unstructured":"Cauwenberghs, E. et al. Positioning the preventive potential of microbiome treatments for cystic fibrosis in the context of current therapies. Cell Rep. Med. 5, 101371 (2024).","journal-title":"Cell Rep. Med."},{"issue":"Suppl 27","key":"32565_CR51","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/pai.13619","volume":"33","author":"S Manti","year":"2022","unstructured":"Manti, S. et al. Type 2 inflammation in cystic fibrosis: New insights. Pediatr Allergy Immunol 33(Suppl 27), 15\u201317 (2022).","journal-title":"Pediatr Allergy Immunol"},{"key":"32565_CR52","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1164\/rccm.202310-1836OC","volume":"209","author":"J Loske","year":"2024","unstructured":"Loske, J. et al. Pharmacological improvement of cystic fibrosis transmembrane conductance regulator function rescues airway epithelial homeostasis and host defense in children with cystic fibrosis. Am. J. Respir. Crit. Care Med. 209, 1338\u20131350 (2024).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"32565_CR53","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.1172\/JCI73469","volume":"124","author":"AG Henderson","year":"2014","unstructured":"Henderson, A. G. et al. Cystic fibrosis airway secretions exhibit mucin hyperconcentration and increased osmotic pressure. J. Clin. Invest. 124, 3047\u20133060 (2014).","journal-title":"J. Clin. Invest."},{"key":"32565_CR54","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.jcf.2022.04.016","volume":"21","author":"MR Pinezich","year":"2022","unstructured":"Pinezich, M. R. et al. Pathological remodeling of distal lung matrix in end-stage cystic fibrosis patients. J. Cyst. Fibros 21, 1027\u20131035 (2022).","journal-title":"J. Cyst. Fibros"},{"key":"32565_CR55","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1136\/thx.2009.130260","volume":"65","author":"NJ Sinden","year":"2010","unstructured":"Sinden, N. J. & Stockley, R. A. Systemic inflammation and comorbidity in COPD: a result of \u201coverspill\u201d of inflammatory mediators from the lungs?. Rev. Evid. Thorax 65, 930\u2013936 (2010).","journal-title":"Rev. Evid. Thorax"},{"key":"32565_CR56","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1378\/chest.08-0412","volume":"135","author":"JA Voynow","year":"2009","unstructured":"Voynow, J. A. & Rubin, B. K. Mucins, mucus, and sputum. Chest 135, 505\u2013512 (2009).","journal-title":"Chest"},{"key":"32565_CR57","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1056\/NEJMoa2411664","volume":"392","author":"JD Chalmers","year":"2025","unstructured":"Chalmers, J. D. et al. Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis. N Engl. J. Med. 392, 1569\u20131581 (2025).","journal-title":"N Engl. J. Med."},{"key":"32565_CR58","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1189\/jlb.0809524","volume":"87","author":"H Grasemann","year":"2010","unstructured":"Grasemann, H. & Ratjen, F. Editorial: leukocyte trafficking and matrix metalloproteinase-8 in obliterative bronchiolitis. J. Leukoc. Biol. 87, 23\u201324 (2010).","journal-title":"J. Leukoc. Biol."},{"key":"32565_CR59","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1358\/dnp.2006.19.10.1068008","volume":"19","author":"R Tirouvanziam","year":"2006","unstructured":"Tirouvanziam, R. Neutrophilic inflammation as a major determinant in the progression of cystic fibrosis. Drug News Perspect. 19, 609\u2013614 (2006).","journal-title":"Drug News Perspect."},{"key":"32565_CR60","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1164\/rccm.201407-1381OC","volume":"191","author":"A Hector","year":"2015","unstructured":"Hector, A. et al. Regulatory T-cell impairment in cystic fibrosis patients with chronic pseudomonas infection. Am. J. Respir Crit. Care Med. 191, 914\u2013923 (2015).","journal-title":"Am. J. Respir Crit. Care Med."},{"key":"32565_CR61","doi-asserted-by":"publisher","first-page":"652410","DOI":"10.3389\/fnut.2021.652410","volume":"8","author":"EJ Derbyshire","year":"2021","unstructured":"Derbyshire, E. J. & Calder, P. C. Bronchiectasis-Could Immunonutrition Have a Role to Play in Future Management?. Front. Nutr. 8, 652410 (2021).","journal-title":"Front. Nutr."},{"key":"32565_CR62","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.ccm.2022.06.004","volume":"43","author":"EM Bruscia","year":"2022","unstructured":"Bruscia, E. M. & Bonfield, T. L. Update on Innate and Adaptive Immunity in Cystic Fibrosis. Clin Chest Med 43, 603\u2013615 (2022).","journal-title":"Clin Chest Med"},{"key":"32565_CR63","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1056\/NEJMoa2411664","volume":"392","author":"JD Chalmers","year":"2025","unstructured":"Chalmers, J. D. et al. Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis. N Engl J Med 392, 1569\u20131581 (2025).","journal-title":"N Engl J Med"},{"key":"32565_CR64","doi-asserted-by":"publisher","first-page":"2401551","DOI":"10.1183\/13993003.01551-2024","volume":"65","author":"JD Chalmers","year":"2025","unstructured":"Chalmers, J. D. et al. Cathepsin C (dipeptidyl peptidase 1) inhibition in adults with bronchiectasis: AIRLEAF, a phase II randomised, double-blind, placebo-controlled, dose-finding study. Eur Respir J 65, 2401551 (2025).","journal-title":"Eur Respir J"},{"key":"32565_CR65","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1136\/thorax.56.4.306","volume":"56","author":"NR Henig","year":"2001","unstructured":"Henig, N. R., Tonelli, M. R., Pier, M. V., Burns, J. L. & Aitken, M. L. Sputum induction as a research tool for sampling the airways of subjects with cystic fibrosis. Thorax 56, 306\u2013311 (2001).","journal-title":"Thorax"},{"key":"32565_CR66","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1136\/thx.53.11.953","volume":"53","author":"A Bhowmik","year":"1998","unstructured":"Bhowmik, A., Seemungal, T. A., Sapsford, R. J., Devalia, J. L. & Wedzicha, J. A. Comparison of spontaneous and induced sputum for investigation of airway inflammation in chronic obstructive pulmonary disease. Thorax 53, 953\u2013956 (1998).","journal-title":"Thorax"},{"key":"32565_CR67","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00616-2025","author":"H Nussstein","year":"2025","unstructured":"Nussstein, H. et al. Changes in sputum viscoelastic properties and airway inflammation in primary ciliary dyskinesia are comparable to cystic fibrosis on elexacaftor\/tezacaftor\/ivacaftor therapy. Eur. Respir. J. https:\/\/doi.org\/10.1183\/13993003.00616-2025 (2025).","journal-title":"Eur. Respir. J."},{"key":"32565_CR68","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1136\/thorax-2022-219943","volume":"78","author":"M Casey","year":"2023","unstructured":"Casey, M. et al. Effect of elexacaftor\/tezacaftor\/ivacaftor on airway and systemic inflammation in cystic fibrosis. Thorax 78, 835\u2013839 (2023).","journal-title":"Thorax"},{"key":"32565_CR69","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.jcf.2025.05.006","volume":"24","author":"JT Duong","year":"2025","unstructured":"Duong, J. T. et al. Fecal microbiota changes in people with cystic fibrosis after 6 months of elexacaftor\/tezacaftor\/ivacaftor: Findings from the promise study. J. Cyst. Fibros. 24, 792 (2025).","journal-title":"J. Cyst. Fibros."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-32565-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-32565-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-32565-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T11:02:07Z","timestamp":1766574127000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-32565-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["32565"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-32565-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,24]]},"assertion":[{"value":"1 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M.A.M. reports grants from the German Research Foundation, the German Innovation Fund, and Vertex Pharmaceuticals outside of the submitted work. Additionally, he reports receipt of consulting fees from Boehringer Ingelheim, Enterprise Therapeutics, Kither Biotec, Splisense, and Vertex Pharmaceuticals, of honoraria for lectures from Vertex Pharmaceuticals Incorporated and participation in advisory boards from Boehringer Ingelheim, Enterprise Therapeutics, Kither Biotec, Pari, Vertex Pharmaceuticals, and of payment for travel from Vertex Pharmaceuticals Incorporated and Boehringer Ingelheim, all outside of the submitted work. He is a Fellow of ERS (FERS). C.S. reports grants from the NIH (R01GM127631, R01AI141549) outside the submitted work. Additionally, he reports receipt of consulting fees from SiChem GmbH, Bremen. All other authors have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"44418"}}